Outcomes of delayed cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitor therapy.
Mohamed Soufi(CancerCare Manitoba), Jeffrey Graham(CancerCare Manitoba), Zineb Hamilou(Centre Hospitalier de l’Université de Montréal), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Frédéric Pouliot(Université Laval), Ramy Saleh(McGill University Health Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Lori Wood(Dalhousie University), Vincent Castonguay(Centre hospitalier universitaire de Québec), Daniel Yick Chin Heng(University of Calgary), Rodney Breau(Ottawa Hospital), Naveen S. Basappa(University of Alberta), Sunita Ghosh(University of Alberta), Dominick Bosse(University of Ottawa), Christian K. Kollmannsberger(BC Cancer Agency), Camilla Tajzler, Antonio Finelli(University of Toronto), Simon Tanguay(McGill University Health Centre)
Cited by 0
Related Papers
Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling
|Molecular Cancer Research|2018|322
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225